Canadian Consensus for Biomarker Testing and Treatment of TRK Fusion Cancer in Adults †

The tyrosine receptor kinase (TRK) inhibitors larotrectinib and entrectinib were recently approved in Canada for the treatment of solid tumours harbouring neurotrophic tyrosine receptor kinase (NTRK) gene fusions. These NTRK gene fusions are oncogenic drivers found in most tumour types at a low freq...

Descripción completa

Detalles Bibliográficos
Autores principales: Bebb, D. Gwyn, Banerji, Shantanu, Blais, Normand, Desmeules, Patrice, Gill, Sharlene, Grin, Andrea, Feilotter, Harriet, Hansen, Aaron R., Hyrcza, Martin, Krzyzanowska, Monika, Melosky, Barbara, Noujaim, Jonathan, Purgina, Bibiana, Ruether, Dean, Simmons, Christine E., Soulieres, Denis, Torlakovic, Emina Emilia, Tsao, Ming-Sound
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Guidelines
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7903287/
https://www.ncbi.nlm.nih.gov/pubmed/33467570
http://dx.doi.org/10.3390/curroncol28010053

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7903287/
https://www.ncbi.nlm.nih.gov/pubmed/33467570
http://dx.doi.org/10.3390/curroncol28010053

Ejemplares similares